Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Company profile
Ticker
TEVA, TEVA-MM
Exchange
Website
CEO
Kaare Schultz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK
Corporate docs
Subsidiaries
Actavis Group • Actavis International Limited • Actavis U.K. Group Ltd. • Arrow International Limited • Mepha Schweiz AG • Merckle GmbH • Pliva Hrvatska d.o.o. • Ratiopharm GmbH • Salomon, Levin & Elstein Ltd. • Teva API B.V. ...
TEVA stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
8 May 24
8-K
Regulation FD Disclosure
18 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
10-K
2023 FY
Annual report
12 Feb 24
8-K
Results of Operations and Financial Condition
31 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
8 Nov 23
Transcripts
TEVA
Earnings call transcript
2023 Q2
2 Aug 23
TEVA
Earnings call transcript
2023 Q1
10 May 23
TEVA
Earnings call transcript
2022 Q4
8 Feb 23
TEVA
Earnings call transcript
2022 Q2
27 Jul 22
TEVA
Earnings call transcript
2022 Q2
27 Jul 22
TEVA
Earnings call transcript
2022 Q1
3 May 22
TEVA
Earnings call transcript
2021 Q4
9 Feb 22
TEVA
Earnings call transcript
2021 Q3
27 Oct 21
TEVA
Earnings call transcript
2021 Q2
28 Jul 21
TEVA
Earnings call transcript
2021 Q1
28 Apr 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.25 bn | 2.25 bn | 2.25 bn | 2.25 bn | 2.25 bn | 2.25 bn |
Cash burn (monthly) | 140.00 mm | 666.67 k | (no burn) | 95.33 mm | (no burn) | (no burn) |
Cash used (since last report) | 1.03 bn | 4.91 mm | n/a | 701.61 mm | n/a | n/a |
Cash remaining | 1.22 bn | 2.25 bn | n/a | 1.55 bn | n/a | n/a |
Runway (months of cash) | 8.7 | 3367.6 | n/a | 16.2 | n/a | n/a |
Institutional ownership, Q4 2023
6.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 78 |
Opened positions | 9 |
Closed positions | 361 |
Increased positions | 18 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 130.92 bn |
Total shares | 67.58 mm |
Total puts | 0.00 |
Total calls | 16.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Europacific Growth Fund | 52.75 mm | $813.41 mm |
AustralianSuper Pty | 9.04 mm | $94.37 bn |
Mivtachim The Workers Social Insurance Fund | 1.45 mm | $15.17 mm |
Assenagon Asset Management | 579.56 k | $6.05 bn |
SG Americas Securities | 544.88 k | $5.69 mm |
Asset Management One | 452.67 k | $4.74 bn |
Tobam | 362.07 k | $3.78 mm |
Financial Sense Advisors | 250.00 k | $2.61 bn |
ARK Investment Management | 222.81 k | $2.33 bn |
Raymond James & Associates | 206.71 k | $2.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | McAvoy David R. | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 66,964 | 0.00 | 66,964 |
4 Mar 24 | Christine Fox | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 81,845 | 0.00 | 81,845 |
4 Mar 24 | Angus Grant | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 52,083 | 0.00 | 52,083 |
4 Mar 24 | Vikki L Conway | Ordinary Shares | Sell | Dispose S | No | Yes | 13.3733 | 2,042 | 27.31 k | 11,692 |
4 Mar 24 | Vikki L Conway | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 7,117 | 0.00 | 13,734 |
4 Mar 24 | Vikki L Conway | Ordinary Shares | Sell | Dispose S | No | Yes | 13.3733 | 1,490 | 19.93 k | 6,617 |
4 Mar 24 | Vikki L Conway | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 33,482 | 0.00 | 33,482 |
4 Mar 24 | Vikki L Conway | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 7,117 | 0.00 | 14,237 |
3 Mar 24 | Vikki L Conway | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 5,179 | 0.00 | 8,107 |
3 Mar 24 | Vikki L Conway | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 5,179 | 0.00 | 15,538 |
News
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $20
9 May 24
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
8 May 24
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
8 May 24
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
8 May 24
Wall Street Poised For Muted Open On Mixed Earnings, With More Fed Speeches In Store: Analyst Sees S&P 500 Crossing Late-March High
8 May 24
Press releases
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
8 May 24
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
8 May 24
Teva to Present at the 2024 Bank of America Healthcare Conference
2 May 24
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
2 May 24
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30 Apr 24